Home › Grants › United States › Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and...
Grant (non-repayable) Open now
- Funder
- National Institutes of Health
Funder profile and all of its programs - Amount
- Up to $1,500,000 per award (published on Grants.gov).
- Where
- United States (federal)
- Eligibility
- Open to businesses, self-employed people, nonprofits, colleges, universities, schools or research institutions and state, provincial, local or tribal governments. No cost sharing is required.
- Sectors
- Health and life sciences, Nonprofits and charities, Research and science
- Deadline
- Closes 5 November 2027
- Source
- Grants.gov XML extract (PAR-25-297)
- Last checked
- 2 November 2026
- Funder contacts
- Public organizational contacts on file Unlock full profile / Sign up
From official open data: listed in the official Grants.gov extract on 2026-11-02. The summary is from the official listing; the eligibility line is our plain-language reading of its eligibility codes. Confirm details on the official page.
Related grant lists
Health and life sciences Nonprofits and charities Research and science Governments and public bodies Schools, colleges and research institutions Nonprofits and charities United States United States (national) Federal agency $1 million or more November 2027
Full eligibility results and funder contacts come with Pro and Lifetime, coming soon.
Information only. GrantSift is not affiliated with any funder. A match means a program is likely eligible or worth checking, not that you will be funded. Always confirm details on the official page. Applying through official portals is free.